Bobby W. Sandage, Jr., Ph.D. is a General Partner of Cultivation Capital, with over 30 years in the pharmaceutical industry per his firm profile. He is President and CEO of Euclises Pharmaceuticals, a role he has held since 2015, and previously led Coronado BioSciences through its 2011 public listing as President and CEO. He was Vice President for oncology research and development at Covidien (Mallinckrodt) Pharmaceuticals and spent 19 years as Chief Scientific Officer and EVP Research and Development at Indevus Pharmaceuticals, until its 2009 acquisition by Endo Pharmaceuticals, with earlier senior positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals. He holds a Ph.D. in Clinical Pharmacy from Purdue University and a B.S. in Pharmacy from the University of Arkansas, and is a licensed registered pharmacist. His firm profile lists him as Director and Chairman of Immunophotonics and a Director of Tensive Controls and of Mateon Therapeutics.
Education
Purdue University, Ph.D. Clinical Pharmacy
University of Arkansas, B.S. Pharmacy
Previous Experience
Euclises Pharmaceuticals, President and CEO since 2015 (current)
Coronado BioSciences, President and CEO, through its 2011 public listing
Covidien (Mallinckrodt) Pharmaceuticals, Vice President, oncology research and development
Indevus Pharmaceuticals, Chief Scientific Officer and EVP Research and Development, 19 years, to its 2009 acquisition by Endo Pharmaceuticals
Senior positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals